The relationship between clinical efficacy and efficacy as measured by two versions of the Continuous Performance Test of OROS-Methylphenidate in adults with ADHD: a double blind placebo controlled medication trial.
- Conditions
- ADHD10037176
- Registration Number
- NL-OMON31400
- Lead Sponsor
- Parnassia (Den Haag)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 44
ADHD-combined subtype has been diagnosed according to regular clinical diagnostic procedures
Age 18-55
Patient is able to read and understand Patient Information
Patient has signed Informed Consent Form
Patient is able and willing to fill out questionnaires
Patient is able and willing to meet follow up appointments for the study
- Comorbid disorder (Axis I) that is very severe at intake and that may interfere with need of rapid treatment or with the goals of the study:
Psychosis
Severe current substance abuse or substance dependence (alcohol: more than 2 consumptions per day or for women more than 15 consumptions in total per week or for men more than 21 conusmptions in total per week. Cannabis: more than one joint per day. Hard drugs: exclusion per se);Anxiety and/or mood disorders will be treated with SSRIs before treatment for ADHD starts.;- Use of the following medications within a month prior to participation to the study: stimulants, anti-psychotic medication, clonidine, benzodiazepines, beta-blockers;- Symptoms of dementia, amnestic disorders or other cognitive disorders;- Symptoms of serious Cluster B Axis II psychopathology that may interfere with cooperation to the study;- For women: pregnancy, breastfeeding of lack of suitable contraception;- Mental retardation;- Insufficient fluency in the Dutch language
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method